B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.
B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.